| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.1 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | -0.047 | 0.1 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 0.1 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.049 | 0.1 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.28 | 0.1 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.079 | 0.1 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |